Favorable response to doxorubicin combination chemotherapy does not yield good clinical outcome in patients with metastatic breast cancer with triple-negative phenotype

BACKGROUND: We analyzed the responses to first line treatment and clinical outcomes of metastatic breast cancer patients treated with palliative doxorubicin/cyclophosphamide (AC) according to molecular cancer subtype. METHODS: A retrospective analysis was performed for 110 metastatic breast cancer p...

Descripción completa

Detalles Bibliográficos
Autores principales: Yi, Seong Yoon, Ahn, Jin Seok, Uhm, Ji Eun, Lim, Do Hyoung, Ji, Sang Hoon, Jun, Hyun Jung, Kim, Kyoung Ha, Chang, Myung Hee, Park, Min Jae, Cho, Eun Yoon, La Choi, Yoon, Park, Yeon Hee, Im, Young-Hyuck
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2972282/
https://www.ncbi.nlm.nih.gov/pubmed/20920367
http://dx.doi.org/10.1186/1471-2407-10-527

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2972282/
https://www.ncbi.nlm.nih.gov/pubmed/20920367
http://dx.doi.org/10.1186/1471-2407-10-527

Ejemplares similares